EAST HANOVER, N.J., Oct. 7 /PRNewswire/ -- Novartis Pharmaceuticals Corporation today announced the availability of patient support programs for Gilenya(TM) (fingolimod) 0.5 mg daily, a first-line oral treatment for relapsing forms of multiple sclerosis.

VIENNA, Sept.

- Companies Will Work Together to Protect World's Supply of Donated Blood from Infectious Diseases Until 2025 - Partners Anticipate Continued Expansion into New Global Markets and Development of Innovative New Products, Including Next-Generation PANTHER Instrument - Companies Also Plan Exploratory Collaboration in Pharmacogenomics - Gen-Probe Provides Preliminary 2009 Financial Guidance Including Additional Revenue and Profit from Agreement SAN DIEGO, Jan.

Six versions of the influenza vaccine were approved on Tuesday for the 2008-2009 flu season, U.S. health regulators said.

Dynavax Technologies has signed an agreement with Novartis Vaccines and Diagnostics for the supply and development, and possible commercialization, of Dynavax's novel universal influenza vaccine in collaboration with Novartis.